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CLARITY Organizers 
Harvard Medical School 
 
Dear CLARITY committee, 
 
On behalf of the Omicia/University of Utah/InVitae, (OUI) team, we would like to 
describe our approach to this challenge, our workflow and reports. We have provided an 
executive summary and a detailed report for each family. The executive summary 
includes the findings and clinical recommendations. The detailed reports show the data 
for each test with supporting evidence and some technical interpretation. In this 
document we provide an overview of our team and our analysis strategy.  
 
Our team is composed of three groups: one academic and two commercial. The OUI team 
includes physicians, geneticists, bioinformaticians, computational biologists, and 
software engineers. Two systems have been at the core of our analyses: The Omicia 
OpalTM platform and the InVitae genetic test of known inherited conditions powered by 
LocusDev. Both tools have been central to our analyses, and we have generated clinical 
laboratory-like reports from both systems. The data provided by the organizers have been 
used as is assuming that the variants are all called correctly. As you can see in the Opal 
report, we have tried to assess the data quality, but only at a very high level, given that 
data generation and variant calling has been out of our control, so a detailed sensitivity 
and specificity analysis was not possible. 
 
Opal is a clinical decision support tool that assists in the clinical interpretation of 
genomes and empowers clinical diagnostics by allowing users to identify a very short list 
of candidate disease-genes and variants of relevance to the disease and phenotype of the 
patient. Opal accomplishes this by automatically embedding the contents of patient 
variant files in a rich analysis environment, providing links to additional genome 
annotations, clinical variants from well-established pathogenic variant databases such as 
OMIM and HGMD, and literature cross-references for candidate disease genes and 
variants, and other resources. Most of the interactive analysis and result inspection has 
been performed with Opal, which is a web application system. Data and analyses were 
securely stored, accessed, shared and discussed by the team during the analysis of the 
project, while each team member had a secure, user controlled access to the genome and 
the analyses results and was able to share their results online. 
 
In summary, our analysis strategy was four-pronged: 
 
Test 1. Genome-wide ab initio searches using VAAST. VAAST is a new-in-class, rapid 
probabilistic search tool for identifying damaged genes and their disease-causing variants 
in personal genome sequences, using population data and amino acid substitution 


Ogden Syndrome, in honor of where the first family 
lives, in Ogden, Utah 
Yandell	  M,	  Huﬀ	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  Hu	  H,	  Singleton	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probabilis)c	  disease-­‐gene	  ﬁnder	  for	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  genomes.	  Genome	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  Sep;21(9):
1529-­‐42.	  
Discov	  Med.	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  Jul;12(62):41-­‐55.	  
Moving	  Exome	  and	  WGS	  into	  a	  Clinical	  
Se`ng	  requires	  both	  Analy)c	  and	  
Clinical	  Validity	  
•  Analy)cal	  Validity:	  the	  test	  is	  accurate	  with	  
high	  sensi)vity	  and	  speciﬁcity.	  
•  Clinical	  Validity:	  Given	  an	  accurate	  test	  result,	  
what	  impact	  and/or	  outcome	  does	  this	  have	  
on	  the	  individual	  person?	  
Op)mizing	  Variant	  Calling	  in	  Exomes	  at	  
BGI	  in	  2011	  
•  Agilent	  v2	  44	  MB	  exome	  kit	  
•  Illumina	  Hi-­‐Seq	  for	  sequencing.	  
•  Average	  coverage	  ~100-­‐150x.	  
•  Depth	  of	  sequencing	  of	  >80%	  of	  the	  target	  
region	  with	  >20	  reads	  or	  more	  per	  base	  pair.	  
•  Comparing	  various	  pipelines	  for	  alignment	  and	  
variant-­‐calling.	  
2-­‐3	  rounds	  of	  sequencing	  at	  BGI	  to	  a;ain	  
goal	  of	  >80%	  of	  target	  region	  at	  >20	  reads	  
per	  base	  pair	  
Exome Capture Statistics K24510-84060 K24510-92157-a K24510-84615 K24510-88962 
Target region (bp) 46,401,121  46,401,121  46,401,121  46,257,379  
Raw reads 138,779,950  161,898,170  156,985,870  104,423,704  
Raw data yield (Mb) 12,490  14,571  14,129  9,398  
Reads mapped to genome 110,160,277  135,603,094  135,087,576  83,942,646  
Reads mapped to target region 68,042,793  84,379,239  80,347,146  61,207,116  
Data mapped to target region (Mb) 5,337.69  6,647.18  6,280.01  4,614.47  
Mean depth of target region 115.03 143.25 135.34 99.76 
Coverage of target region (%) 0.9948  0.9947  0.9954  0.9828  
Average read length (bp) 89.91  89.92  89.95  89.75  
Fraction of target covered >=4X 98.17  98.38  98.47  94.25  
Fraction of target covered >=10X 95.18  95.90  95.97  87.90  
Fraction of target covered >=20X 90.12  91.62  91.75  80.70  
Fraction of target covered >=30X 84.98  87.42  87.67  74.69  
Capture specificity (%) 61.52  62.12  59.25  73.16  
Fraction of unique mapped bases on or near target 65.59  65.98  63.69  85.46  
Gender test result M M M F 
Depth	  of	  Coverage	  in	  15	  exomes	  >	  20	  
reads	  per	  bp	  in	  target	  region	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BGI	  appears	  to	  have	  followed	  the	  lead	  of	  the	  
other	  major	  genome	  sequencing	  centers	  
(Broad,	  WashU	  and	  Baylor)	  and	  embraced	  
“Deep	  Exomes”	  at	  this	  point.	  
Pipelines	  Used	  on	  Same	  Set	  of	  Seq	  Data	  by	  Diﬀerent	  
Analysts,	  using	  Hg19	  Reference	  Genome	  
1)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format	  -­‐	  Picard	  to	  remove	  duplicates	  -­‐	  GATK	  (version	  
1.5)	  with	  recommended	  parameters	  	  (GATK	  IndelRealigner,	  base	  quality	  scores	  
were	  re-­‐calibrated	  by	  GATK	  Table	  Recalibra)on	  tool.	  Genotypes	  called	  by	  GATK	  
UniﬁedGenotyper.	  	  
	  
2)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format-­‐Picard	  to	  remove	  duplicates	  -­‐	  SamTools	  version	  
0.1.18	  to	  generate	  genotype	  calls	  	  -­‐-­‐	  The	  “mpileup”	  command	  in	  SamTools	  were	  
used	  for	  iden)fy	  SNPs	  and	  indels.	  
	  
3)  SOAP-­‐Align	  –	  SOAPsnp	  –	  and	  BWA-­‐SOAPindel	  (adopts	  local	  assembly	  based	  on	  an	  
extended	  de	  Bruijn	  graph	  )	  
	  
4)  GNUMAP-­‐SNP	  (probabilis)c	  Pair-­‐Hidden	  Markov	  which	  eﬀec)vely	  accounts	  for	  
uncertainty	  in	  the	  read	  calls	  as	  well	  as	  read	  mapping	  in	  an	  unbiased	  fashion)	  
	  
5)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format	  -­‐	  Picard	  to	  remove	  duplicates	  –	  SNVer	  	  
Total	  SNVs
Mean	  #	  of	  total	  SNVs	  across	  15	  exomes,	  called	  by	  5	  pipelines.	  The	  percentage	  
in	  the	  center	  of	  the	  the	  Venn	  diagram(Parenthesis)	  is	  the	  percent	  of	  total	  SNVs	  
called	  by	  all	  ﬁve	  pipelines.	  	  
A)	  
•  C)	  Mean	  #	  of	  novel	  SNVs	  (not	  present	  in	  dbSNP135)	  found	  by	  5	  pipelines	  across	  15	  
exomes.	  The	  percentage	  in	  the	  center	  of	  the	  Venn	  diagram	  is	  the	  percent	  of	  novel	  
SNVs	  called	  by	  all	  ﬁve	  pipelines.	  
C)	  
Novel	  SNVs	  
Total	  mean	  overlap,	  plus	  or	  minus	  one	  standard	  deviaXon,	  observed	  between	  three	  
indel	  calling	  pipelines:	  GATK,	  SOAP-­‐indel,	  and	  SAMTools.	  	  a)	  Mean	  overlap	  when	  indel	  
posi)on	  was	  the	  only	  necessary	  agreement	  criterion.	  b)	  Mean	  overlap	  when	  indel	  
posi)on,	  base	  length	  and	  base	  composi)on	  were	  the	  necessary	  agreement	  criteria.	  	  	  
Indels-­‐	  Overlap	  by	  Base	  	  
Posi)on	  only	  
Indels-­‐	  Overlap	  by	  Base	  	  
Posi)on,	  Length	  and	  Composi)on	  
INDELS	  
	  
	  
	  
?	   	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  Age	  54	  
	  	  	  	  	  	  	  	  	  	  Age	  25	  	  	  	  	  	  	  	  	  	  	  Age	  24	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Age	  19	  
	   	   	   	   	   	   	  	  	  	  	  	  	  prodromal,	  likely	  bipolar	  
Collected	  35	  DNA	  samples	  from	  the	  extended	  family,	  due	  to	  very	  large	  excess	  of	  
major	  depression,	  	  bipolar,	  Tourere	  and	  OCD.	  
Another	  Pedigree	  –K8101	  
Case	  PresentaXon	  
 Male,	  age	  55	  currently.	  
 Psycho)c	  break	  at	  age	  20	  with	  bipolar	  features.	  
 Evolu)on	  into	  schizoaﬀec)ve	  disorder	  over	  next	  25	  years.	  
 Also	  with	  severe	  obsessive	  compulsive	  disorder	  and	  severe	  Tourere	  Syndrome	  
 At	  least	  two	  very	  severe	  suicide	  arempts	  at	  age	  22,	  including	  throwing	  self	  
under	  a	  truck	  one	  )me	  and	  then	  driving	  head-­‐on	  into	  another	  car	  (with	  death	  
of	  two	  passengers	  in	  other	  car,	  found	  not	  guilty	  by	  reason	  of	  insanity).	  
 Extensive	  medica)on	  trials	  over	  many	  years,	  along	  with	  anterior	  capsulotomy	  
with	  very	  lirle	  eﬀect	  for	  the	  OCD.	  
	  
 Current	  meds:	  
	  	  	  	  	  	  	  	  	  Klonopin	  	  
	  Nico)namide	  
	  Lunesta 	   	   	   	  	  
	  A)van	  
	  
	  	  
	  	  
	  Lithium	  
	  Seroquel	  
	  Lamictal	  
	  Luvox	  
	  
	  	  
Complete	  Genomics	  chemistry	  -­‐	  combinatorial	  
probe	  anchor	  liga)on	  (cPAL)	  
homozygous reference criteria are considered not called. 
Genome-Genome-Genome comparisons are performed 
using CGATM Tools v1.512 calldiff, snpdiff, and testvariants 
methods, which take into account complex variants (for 
example, loci with a SNP on one allele and a substitution 
on another) and called versus no-called sites.
Call rate and coverage: Call rate and coverage data 
are averaged over all shipments from Q3 2011 to Q1 
2012. Call rate and coverage are both measured relative 
to the 2.85GB Build 37 reference genome (excluding 
random contigs). Exome call rates are from Q1 2012 and 
are relative to RefSeq 37.2 gene models. They are up 
from the 2011 exome call rates, which averaged 95%-
96%.
There are many ways to measure coverage. Complete 
Genomics uses the gross mapped coverage (single 
and paired, unique and non-unique) from the 
coverageRefScore and summary !les11. Attributes 
of recent Complete Genomics data in the literature 
(speci!cally papers where call rate and/or coverage were 
reported) are described in Table 1. Improvements to 
call rate over time are clear from these results and have 
continued since this analysis was performed.
Trio Analysis: Called VQHIGH and homozygous 
reference sites from the YRI family trio were processed 
with the CGA Tools 1.5 listvariants and testvariants 
commands, and additional analysis was performed 
to extract MIEs. All sites fully called in the trio were 
considered, including sites called either variant or 
reference in the child. Repetitive sequences were de!ned 
using the union of the RepeatMasker, SegDup, and 
Simple Repeats tracks from the UCSC genome browser 
(genome.ucsc.edu), which collectively cover about 
53.7% of the reference genome.
Clustered MIE Analysis: The genome was segmented 
into non-overlapping windows containing 50kb of fully 
called genomic bases each, which were then sorted by 
the number of MIEs contained within each block. This 
list was then traversed until 30% of the total MIEs were 
encountered.
Technical Replicates: Two libraries independently 
constructed from NA19240 DNA were sequenced and 
analyzed. Sites called variant at VQHIGH in replicate 1 
and reference (RefScore>10) in replicate 2 were counted 
as discordant. A Bayesian statistical model was used to 
partition all discordances into putative FPs in replicate 
1 versus FNs in replicate 2 (see Reference 11, Score 
Calibration Documentation) (Table 2).
Calculation of the FP:FN tradeoff in direct 
comparisons of technical replicates: The CGA Tools 
1.5 calldiff command was used to compute the somatic 
score for each discordance between technical replicates. 
Sites called heterozygous or homozygous at a variant in 
replicate 1, and reference (for both alleles) in replicate 2, 
were counted as discordant. 
False Positive Rate: 2009 data were published in 
Reference 2. 2010 data were published in Reference 5, 
see Table 3.
Ti/Tv analysis: See References 7 and 8. Ti/Tv is 
reported for all genomes delivered from Q3 2011 to 
Q1 2012. The Ti/TV ratios in the 69 publicly available 
Complete Genomics genomes are in the same range. 
FALSE POSITIVES EST FPs FALSE NEGATIVES TOTAL DISCORDANCES CONCORDANCE
Discordant SNVs per called MB 1.56 x 10-6 4,450 1.67 x 10-6 3.23 x 10-6 99.9997% of bases
Table 2. Concordance of Technical Replicates.
COMPLETE GENOMICS CALL
OTHER PLATFORM PLATFORM-
SPECIFIC SNVs
VALIDATION RATE EST FPs FPR
Het or Hom SNV No SNV Reported 99K 17/18 = 94.4% 5,577 0.16%
No-call or Hom-Ref SNV Reported 345K 2/15 = 13.3% 299,115 8.2%
Table 3. False Positive Rate.
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Accuracy of Complete Genomics Whole 
Human Genome Sequencing Data
Analysis Pipeline v2.0
High accuracy is critical to the effective use of whole genome sequencing (WGS) data 
by researchers and clinicians alike. Given the size of the human genome, even a small 
error rate can lead to a large total number of errors. Complete Genomics understands 
the importance of accuracy in WGS and we strive to deliver the most accurate data 
to our customers. We describe here some of the key factors to consider in measuring 
accuracy and provide an accuracy analysis for our Analysis Pipeline v2.0.
The accuracy of WGS data can be measured by a wide variety of methods, none of 
which is perfect, but many of which are informative for practical use. At the same time, 
accuracy estimates can be slanted to appear better or worse than they are; thus it is 
important that the detailed methods of their calculation be considered along with the 
results.
Techniques to improve variant detection accuracy include read and SNP !ltering 
or increasing call stringency1, but their use leads to a signi!cant and often poorly 
measured cost to sensitivity. Reports in the scienti!c literature show that Complete 
Genomics WGS, which avoids such coarse !ltering approaches, not only produces the 
lowest error rates but also does so at the highest call rates.
Complete Genomics’ approach to WGS is described below along with some 
suggestions on what to look for in measuring and comparing the accuracy of different 
sequencing approaches.
Result
Coverage and Call Rate: A key to Complete Genomics’ approach to WGS is deep 
sequencing. Complete Genomics has delivered more than 55x average gross coverage 
for all customer genomes shipped since the launch of its service. Complete Genomics 
applies an advanced bioinformatics pipeline using local de novo assembly to generate 
all small variant calls2,3, and using these methods currently achieves mean genome-
wid  call rat s of more than 97%, while call rat s in coding regions currently average 
gr ater th n 98%. These results are corroborated by rec nt reports of Complete 
Genomics’ data in the scienti!c literature (see Table 1 below).
WHITE PAPER
Taking	  SNVs	  concordant	  in	  5	  Illumina	  pipelines,	  
and	  comparing	  to	  SNVs	  in	  Complete	  Genomics	  
Data	  from	  same	  sample	  	  
Taking	  SNVs	  concordant	  in	  5	  Illumina	  pipelines	  
as	  per	  READ	  DEPTH,	  and	  comparing	  to	  SNVs	  in	  
Complete	  Genomics	  Data	  from	  same	  sample	  
Taking	  SNVs	  found	  by	  ALL	  5	  Illumina	  pipelines	  
(Union),	  and	  comparing	  to	  SNVs	  in	  Complete	  
Genomics	  Data	  from	  same	  sample	  
Taking	  the	  UNION	  of	  all	  SNVs	  called	  by	  Illumina	  
pipelines,	  as	  per	  READ	  DEPTH,	  and	  comparing	  to	  SNVs	  
in	  Complete	  Genomics	  Data	  from	  same	  sample	  
Comparing	  the	  UNION	  versus	  the	  
CONCORDANCE	  of	  5	  pipelines	  to	  the	  Complete	  
Genomics	  Data	  
Union	  of	  Illumina	  variants	   Concordant	  Illumina	  variants	  
Read	  Depth	  of	  Illumina	  Reads	  for	  variants	  
called	  by	  Complete	  Genomics	  but	  NOT	  by	  
GATK	  or	  SOAP	  pipelines	  
Read depth of
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Read depth taken from GATK bam file
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Read	  Depth	  of	  Illumina	  Reads	  for	  variants	  
called	  by	  Complete	  Genomics	  but	  NOT	  by	  
GNUMAP,	  SNVer	  or	  SamTools	  pipelines	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Fr
eq
ue
nc
y
0 200 400 600 800 1000
0
20
0
40
0
60
0
80
0
Read depth of
SNVs called by CG
and not SAMTools
Read depth taken from SAMtools bam file
Fr
eq
ue
nc
y
0 200 400 600
0
20
0
40
0
60
0
80
0
10
00
Read depth of
SNVs called by CG
and not SNVer
Read depth taken from SNVer bam file
Fr
eq
ue
nc
y
0 200 400 600 800
0
20
0
40
0
60
0
80
0
10
00
Genomic Dark Matter: The reliability of short read
mapping illustrated by the Genome Mappability Score
Hayan Lee1,2∗and Michael C. Schatz 1,2
1Department of Computer Science, Stony Brook University, Stony Brook, NY
2Simons Center for Quantitive Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
ABSTRACT
Motivation: Genome resequencing and short read mapping are two
of the primary tools of genomics and are used for many important
applications. The current state-of-the-art in mapping uses the quality
values and mapping quality scores to evaluate the reliability of the
mapping. These attributes, however, are assigned to individual
reads and don’t directly measure the problematic repeats across
the genome. Here we present the Genome Mappability Score
(GMS) as a novel measure of the complexity of resequencing a
genome. The GMS is a weighted probability that any read could be
unambiguously mapped to a given position, and thus measures the
overall composition of the genome itself.
Results: We have developed the Genome Mappability Analyzer
(GMA) to compute the GMS of every position in a genome. It
leverages the parallelism of cloud computing to analyze large
genomes, and enabled us to identify the 5-14% of the human,
mouse, fly, and yeast genomes that are difficult to analyze with short
reads. We examined the accuracy of the widely used BWA/SAMtools
polymorphism discovery pipeline in the context of the GMS, and
found discovery errors are dominated by false negatives, especially in
regions with poor GMS. These errors are fundamental to the mapping
process and cannot be overcome by increasing coverage. As such,
the GMS should be considered in every resequencing project to
pinpoint the dark matter of the genome, including of known clinically
relevant variations in these regions.
Availability: The source code and profiles of several model
organisms are available at http://gma-bio.sourceforge.net
Contact: hlee@cs.stonybrook.edu
1 INTRODUCTION
1.1 Background
DNA sequencing technology has dramatically improved in the past
decade so that today an individual human genome can be sequenced
for less than $10,000 and in less then two weeks (Drmanac et al.,
2010), compared to years of effort and hundreds of millions
of dollars for the first sequenced human genome (Stein, 2010).
This dramatic improvement has lead to an exponential growth in
sequencing, including several large projects to sequence thousands
of human genomes and exomes, such as the 1000 Genomes Project
∗to whom correspondence should be addressed
Consortium (2010) or International Cancer Genome Consortium
(2010). Other projects, such as ENCODE Project Consortium
(2004) and modENCODE Consortium (2010) are extensively using
resequencing and read mapping to discover novel genes and binding
sites.
The output of current DNA sequencing instruments consists of
billions of short, 25− 200 base pairs (bp) sequences of DNA called
reads, with an overall per base error rate around 1%-2% (Bentley
et al., 2008). In the case of whole genome resequencing, these
short reads will originate from random locations in the genome,
but nevertheless, entire genomes can be accurately studied by
oversampling the genome, and then aligning or ”mapping” each
read to the reference genome to computationally identify where it
originated. Once the entire collection of reads has been mapped,
variations in the sample can be identified by the pileup of reads that
significantly disagree from the reference genome (Fig. 1).
The leading short read mapping algorithms, including BWA (Li
and Durbin, 2009), Bowtie (Langmead et al., 2009), and SOAP (Li
et al., 2009b), all try to identify the best mapping position for each
read that minimizes the number of differences between the read and
the genome, i.e., the edit distance of the nucleotide strings, possibly
weighted by base quality value. This is made practical through
sophisticated indexing schemes, such as the Burrows-Wheeler
transform (Burrows and Wheeler, 1994), so that many billions of
reads can be efficiently mapped allowing for both sequencing errors
and true variations. The primary complication of short read mapping
is that a read may map equally well or nearly equally well to
multiple positions because of repetitive sequences in the genome.
Notably, nearly 50% of the human genome consists of repetitive
elements, including certain repeats that occur thousands of times
throughout (International Human Genome Sequencing Consortium,
2001).
For resequencing projects, the fraction of repetitive content
depends on read length and allowed error rate. At one extreme, all
single base reads would be repetitive, while chromosome length
reads would not be repetitive at all. Similarly, increasing the
allowed error rate increases the fraction of the genome that is
repetitive. The short read mapping algorithms use edit distance and
other read characteristics to compute a mapping quality score for
each mapped read (Li et al., 2008). The mapping quality score
estimates the probability that the assigned location is the correct
1
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•  Genome	  Mappability	  Score	  (GMS)	  -­‐-­‐	  measure	  of	  the	  complexity	  of	  resequencing	  a	  
genome	  =	  a	  weighted	  probability	  that	  any	  read	  could	  be	  unambiguously	  mapped	  to	  a	  
given	  posi)on,	  and	  thus	  measures	  the	  overall	  composi)on	  of	  the	  genome	  itself.	  
•  The	  detec) n	  failure	  erro s	  are	  dominated	  by	  false	  nega)v s,	  which	  me ns	  the	  SNP	  
calling	  program	  fails	  to	  ﬁnd	  suc 	  varia) ns.	  In	  par)cular,	  among	  all	  5022	  false	  
nega)ves,	  3505	  (70%)	  are	  located	  in	  low	  GMS	  region,	  and	  only	  1517	  (30%)	  are	  in	  high	  
GMS	  region.	  Consid ring	  o ly	  13-­‐14%	  of	  human	  genome	  is	  low	  GMS	  r gi ,	  
varia)ons	  in	  low	  GMS	  regions	  are	  clearly	  and	  substan)ally	  overrepresented.	  It	  is	  not	  
surprising	  th t	  errors	  are	  dominated	  by	  false	  nega)v s,	  as	  the	  SNP-­‐c lling	  algorithm	  
will	   se	  the	  mapping	  quality	  score	  to	  ﬁlter	  out	  low	  conﬁd nce	  mapping.	  What	  is	  
surprising	  is	  the	  extent	  of	  false	  nega)ves	  and	  the	  concentra)on	  of	  false	  nega)ves	  
alm st	  en)rely	  within	  low	  GMS	  regions.	  	  
	  
•  The	  GMS	  should	  be	  considered	  i 	   ve y	  resequ ncing	   roject	  to	  pinpoi t	  the	  d rk	  
marer	   f	  the	  geno e,	  includi g	  of	  known	  clinic ll 	  relevant	  varia)on 	  in	  these	  
regions.	  
Genomic	  Dark	  Marer,	  cont….	  
•  That	  means	  that	  unlike	  typical	  false	  nega)ves,	  increasing	  coverage	  
will	  not	  help	  iden)fy	  muta)ons	  in	  low	  GMS	  regions,	  even	  with	  0%	  
sequencing	  error.	  	  
•  Instead	  this	  is	  because	  the	  SNP-­‐calling	  algorithms	  use	  the	  mapping	  
quality	  scores	  to	  ﬁlter	  out	  unreliable	  mapping	  assignments,	  and	  low	  
GMS	  regions	  have	  low	  mapping	  quality	  score	  (by	  deﬁni)on).	  Thus	  
even	  though	  many	  reads	  may	  sample	  these	  varia)ons,	  the	  mapping	  
algorithms	  cannot	  ever	  reliably	  map	  to	  them.	  	  
•  Since	  about	  14%	  of	  the	  genome	  has	  low	  GMS	  value	  with	  typical	  
sequencing	  parameters,	  it	  is	  expected	  that	  about	  14%	  of	  all	  
varia)ons	  of	  all	  resequencing	  studies	  will	  not	  be	  detected.	  	  
•  To	  demonstrate	  this	  eﬀect,	  we	  characterised	  the	  SNP	  variants	  
iden)ﬁed	  by	  the	  1000	  genomes	  pilot	  project,	  and	  found	  that	  
99.99%	  of	  the	  SNPs	  reported	  were	  in	  high	  GMS	  regions	  of	  the	  
genome,	  and	  in	  fact	  99.95%	  had	  GMS	  over	  90.	  	  
To	  conclude,	  results	  from	  Exome	  and	  WGS	  
requires	  both	  AnalyXc	  and	  Clinical	  Validity	  
•  Analy)cal	  Validity:	  the	  test	  is	  accurate	  with	  
high	  sensi)vity	  and	  speciﬁcity.	  
•  Clinical	  Validity:	  Given	  an	  accurate	  test	  result,	  
what	  impact	  and/or	  outcome	  does	  this	  have	  
on	  the	  individual	  person.	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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  Talk	  
Op)mizing	  the	  Variant	  Calling	  Pipeline	  
Using	  Family	  Rela)onships	  
We	  looked	  for	  SNVs	  that	  were	  detected	  in	  children	  but	  
not	  in	  parents	  using	  3	  diﬀerent	  strategies:	  
	  	  
1.	  We	  used	  all	  of	  the	  SNVs	  that	  were	  detected	  by	  all	  5	  
pipelines	  for	  both	  parents	  and	  children	  
2.	  We	  used	  all	  of	  the	  detected	  SNVs	  for	  parents,	  but	  only	  
the	  concordant	  SNVs	  between	  the	  5	  diﬀerent	  pipelines	  
for	  children.	  
3.	  We	  used	  SNVs	  concordant	  between	  the	  5	  diﬀerent	  
pipelines	  for	  children	  and	  parents.	  
	  	  
Op)mizing	  pipeline	  based	  on	  literature	  value	  of	  ~1	  
true	  de	  novo	  protein-­‐altering	  muta)on	  per	  exome	  
The	  result	  is	  that	  using	  all	  of	  the	  detected	  SNVs	  for	  both	  parents	  and	  children	  should	  
minimize	  the	  false	  nega)ve	  rate	  but	  similarly	  show	  a	  rela)vely	  high	  false	  posi)ve	  rate.	  	  
Using	  all	  of	  the	  SNVs	  detected	  for	  parents	  but	  only	  the	  SNVs	  concordant	  among	  the	  ﬁve	  
pipelines	  shows	  muta)on	  rates	  similar	  to	  those	  reported	  by	  the	  literature	  and	  is	  expected	  
to	  have	  moderate	  false	  posi)ve	  rates	  and	  moderate	  false	  nega)ve	  rates.	  	  Using	  only	  the	  
SNVs	  concordant	  among	  the	  5	  diﬀerent	  pipelines	  for	  both	  parents	  and	  children	  should	  
minimize	  the	  false	  posi)ve	  rate	  but	  similarly	  show	  a	  rela)vely	  high	  false	  nega)ve	  rate.	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“Parents”	  
Analysis	  based	  on	  various	  pipelines	  
•  “Parents”	  in	  this	  case	  means	  the	  mother,	  father	  
AND	  grandmother.	  
•  Taking	  the	  Union	  of	  SNVs	  from	  all	  5	  pipelines	  
from	  “Parents”,	  and	  subtract	  that	  from	  the	  Union	  
of	  all	  SNVs	  in	  each	  child.	  
•  Or	  Subtract	  the	  Union	  of	  these	  “Parents”	  from	  
the	  SNVs	  in	  the	  child	  concordant	  between	  5	  
pipelines.	  
•  Or,	  subtract	  the	  concordant	  variants	  from	  5	  
pipelines	  in	  “Parents”	  from	  the	  concordant	  
variants	  for	  5	  pipelines	  in	  each	  child.	  
	  
All#SNVs,#both#for#
parents#and#children,#
were#considered
All#parental#SNVs#that#were#detected#
were#considered.##Only#SNVs#concordant#
between#the#5#pipelines#were#considered#
for#children#
SNVs#concordant#between#5#
pipelines#for#children#and#
parents
Number#of##SNVs#found#in#child#A#
but#not#in#parents
1057 2 637
Number#of##SNVs#found#in#child#B#
but#not#in#parents
1084 1 672
Number#of##SNVs#found#in#child#C#
but#not#in#parents
2363 20 1703
Number#of##SNVs#found#in#child#D#
but#not#in#parents
1518 5 876
Number#of#nonsyn#SNVs#in#child#A#
but#not#in#parents
411 1 150
Number#of#nonsyn#SNVs#in#child#B#
but#not#in#parents
396 0 135
Number#of#nonsyn#SNVs#in#child#C#
but#not#in#parents
911 6 459
Number#of#nonsyn#SNVs#in#child#D#
but#not#in#parents
619 3 225
Number#of#shared#nonsyn#SNVs#in#
the#children,#but#not#in#parents
8 0 9

Preliminary	  Conclusions	  
•  Sequencing	  a	  grandparent	  seems	  to	  help	  
eliminate	  errors	  derived	  from	  the	  current	  depth	  of	  
sequencing	  coverage	  in	  the	  mother	  and	  father.	  	  
•  An	  alterna)ve	  might	  be	  just	  deeper	  depth	  of	  
sequencing	  in	  the	  parents,	  although	  s)ll	  
inves)ga)ng	  errors	  that	  might	  be	  overcome	  by	  
sequencing	  a	  grandparent.	  
•  Need	  to	  decide	  on	  whether	  to	  proceed	  with	  the	  
concordance	  of	  2	  or	  more	  pipelines,	  like	  SOAP	  +	  
GATK,	  or	  just	  accept	  (with	  everybody	  else	  it	  
seems!)	  that	  GATK	  is	  somehow	  the	  “de	  facto	  
standard”.	  
VAAST	  shows	  that	  probabilis)c	  ranking	  
will	  be	  very	  useful	  going	  forward	  
•  But,	  VAAST	  is	  currently	  dependent	  on	  the	  variant	  lists	  
provided	  to	  it,	  as	  there	  is	  s)ll	  a	  heuris)c	  threshold	  with	  
input	  of	  variant	  data,	  i.e.	  no	  probabilis)c	  weigh)ng	  of	  
SNV	  or	  indel	  “true	  posi)ve	  likelihood”.	  
•  Therefore,	  currently	  need	  to	  op)mize	  variant-­‐calling	  to	  
make	  sure	  variants	  provided	  are	  correct.	  Plus,	  VAAST	  
chokes	  if	  background	  genomes	  are	  full	  of	  false	  
posi)ves.	  
•  Thus,	  focused	  now	  on	  comprehensive	  comparison	  of	  
NGS	  variant-­‐calling	  on	  deep	  exome	  sequencing	  data	  
Preliminary	  Conclusions	  
•  Sequencing	  a	  grandparent	  seems	  to	  help	  
eliminate	  errors	  derived	  from	  the	  current	  depth	  of	  
sequencing	  coverage	  in	  the	  mother	  and	  father.	  	  
•  An	  alterna)ve	  might	  be	  just	  deeper	  depth	  of	  
sequencing	  in	  the	  parents,	  although	  s)ll	  
inves)ga)ng	  errors	  that	  might	  be	  overcome	  by	  
sequencing	  a	  grandparent.	  
•  Need	  to	  decide	  on	  whether	  to	  proceed	  with	  the	  
concordance	  of	  2	  or	  more	  pipelines,	  like	  SOAP	  +	  
GATK,	  or	  just	  accept	  (with	  everybody	  else	  it	  
seems!)	  that	  GATK	  is	  somehow	  the	  “de	  facto	  
standard”.	  
For	  now,	  more	  eﬀort	  should	  be	  placed	  
on	  the	  following:	  
•  Implemen)ng	  Standards	  for	  a	  “clinical-­‐grade”	  exome,	  
and	  promo)ng	  the	  “networking	  of	  science”	  model.	  
•  Focusing	  on	  rare,	  highly	  penetrant	  muta)ons	  running	  
in	  families,	  with	  cascade	  carrier	  tes)ng	  of	  even	  more	  
rela)ves	  as	  needed.	  
•  The	  genomic	  background	  is	  much	  more	  constant	  in	  
families.	  
•  The	  environmental	  background	  is	  some)mes	  more	  
constant	  in	  families.	  
•  This	  allows	  one	  to	  ﬁgure	  out	  penetrance	  of	  rare	  
variants	  in	  these	  families,	  along	  with	  other	  issues,	  
such	  as	  soma)c	  mosaicism.	  
